Alnylam gains on positive mid-stage RSV data

Shares of Alnylam surged this morning on the news that mid-stage data for its experimental respiratory drug demonstrated a positive response with statistically significant anti-viral activity. Researchers were testing ALN-RSV01 against respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age

"We are very pleased with the results of [the study] and look forward to advancing this program to its next stage of development, a Phase II study in naturally infected adult patients which we expect to initiate in the first half of this year," Chief Executive John Maraganore said.

- see this release for more

Related Articles:
Is Alnylam Roche's 'second Genentech'? Report
Roche harnesses Alnylam's RNAi tech in $1B deal. Report
RNAi leaders Isis, Alnylam form new company. Report